AXSM Quote, Financials, Valuation and Earnings

Ocular Therapeutix has a net margin of -48.92% compared to Axsome Therapeutics's net margin of -598.74%. Axsome Therapeutics's return on equity of -309.19% beat Ocular Therapeutix's return on equity of -56.05%.

Axsome Therapeutics has a consensus price target of $176.79, signalling upside risk potential of 57.51%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.92 which suggests that it could grow by 57.44%. Given that Axsome Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Axsome Therapeutics is more attractive than Ocular Therapeutix.

Axsome Therapeutics has a beta of 0.459, which suggesting that the stock is 54.053% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.431, suggesting its more volatile than the S&P 500 by 43.081%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. Axsome Therapeutics's net income of -$59.4M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.54x versus 31.97x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -48.92% compared to Axsome Therapeutics's net margin of 73.68%. Axsome Therapeutics's return on equity of -309.19% beat PTC Therapeutics's return on equity of --.

Axsome Therapeutics has a consensus price target of $176.79, signalling upside risk potential of 57.51%. On the other hand PTC Therapeutics has an analysts' consensus of $62.81 which suggests that it could grow by 29.43%. Given that Axsome Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Axsome Therapeutics is more attractive than PTC Therapeutics.

Axsome Therapeutics has a beta of 0.459, which suggesting that the stock is 54.053% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.905%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are smaller than PTC Therapeutics quarterly revenues of $1.2B. Axsome Therapeutics's net income of -$59.4M is lower than PTC Therapeutics's net income of $866.6M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is 7.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.54x versus 2.17x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -48.92% compared to Axsome Therapeutics's net margin of 4.19%. Axsome Therapeutics's return on equity of -309.19% beat TG Therapeutics's return on equity of 19.78%.

Axsome Therapeutics has a consensus price target of $176.79, signalling upside risk potential of 57.51%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 3.34%. Given that Axsome Therapeutics has higher upside potential than TG Therapeutics, analysts believe Axsome Therapeutics is more attractive than TG Therapeutics.

Axsome Therapeutics has a beta of 0.459, which suggesting that the stock is 54.053% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Axsome Therapeutics's net income of -$59.4M is lower than TG Therapeutics's net income of $5.1M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 163.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.54x versus 16.31x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -48.92% compared to Axsome Therapeutics's net margin of 23.33%. Axsome Therapeutics's return on equity of -309.19% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Axsome Therapeutics has a consensus price target of $176.79, signalling upside risk potential of 57.51%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.23 which suggests that it could grow by 7.98%. Given that Axsome Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Axsome Therapeutics is more attractive than Vertex Pharmaceuticals.

Axsome Therapeutics has a beta of 0.459, which suggesting that the stock is 54.053% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Axsome Therapeutics's net income of -$59.4M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.54x versus 10.81x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.